Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis
Authors
Keywords
-
Journal
BJS Open
Volume 6, Issue 3, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-02-15
DOI
10.1093/bjsopen/zrac028
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin®) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin)
- (2021) MARCUS SCHMIDT et al. ANTICANCER RESEARCH
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
- (2021) Larissa A. Korde et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer – A retrospective cohort study
- (2021) Matthew G. Davey et al. BREAST
- Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis.
- (2020) Laura M. Spring et al. CLINICAL CANCER RESEARCH
- Prognostic value of residual disease after neoadjuvant therapy in HER2+ breast cancer evaluated by Residual Cancer Burden, Neoadjuvant Response Index & Neo-Bioscore
- (2019) Tessa G Steenbruggen et al. CLINICAL CANCER RESEARCH
- Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy
- (2019) Joanne W Chiu et al. POSTGRADUATE MEDICAL JOURNAL
- Insulin-like growth factor-1, metabolic abnormalities, and pathological complete remission rate in HER2-positive breast cancer patients receiving neoadjuvant therapy
- (2019) Yi-wei Tong et al. OncoTargets and Therapy
- Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
- (2019) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
- (2019) Helena M Earl et al. LANCET
- Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
- (2019) Sandra M. Swain et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab
- (2019) Noriko Fujita et al. ONCOLOGY
- Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy
- (2018) Waqar Haque et al. BREAST CANCER RESEARCH AND TREATMENT
- Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
- (2018) Andreas Schneeweiss et al. EUROPEAN JOURNAL OF CANCER
- A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results
- (2018) X. Pivot et al. EUROPEAN JOURNAL OF CANCER
- Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
- (2018) Michail Ignatiadis et al. JNCI-Journal of the National Cancer Institute
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
- (2018) Bernard Asselain et al. LANCET ONCOLOGY
- Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
- (2018) Hikmat Abdel-Razeq et al. OncoTargets and Therapy
- Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
- (2018) Michail Ignatiadis et al. JNCI-Journal of the National Cancer Institute
- The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT)
- (2018) Oluwadamilola M. Fayanju et al. ANNALS OF SURGERY
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status
- (2017) Sylvie Giacchetti et al. EUROPEAN JOURNAL OF CANCER
- Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
- (2017) W. Fraser Symmans et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer
- (2017) Laura Spring et al. Journal of the National Comprehensive Cancer Network
- Pathological responses and long-term outcome analysis after neoadjuvant chemotheraphy in breast cancer patients from Kuwait over a period of 15 years
- (2017) Yamini Krishnan et al. ANNALS OF SAUDI MEDICINE
- Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer.
- (2017) A. Gropper et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy
- (2016) Cynthia Villarreal-Garza et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
- (2016) B. Ingold Heppner et al. CLINICAL CANCER RESEARCH
- Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study
- (2016) Y. Zhang et al. EJSO
- HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up
- (2016) Christian Jackisch et al. EUROPEAN JOURNAL OF CANCER
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
- (2016) Luca Gianni et al. LANCET ONCOLOGY
- Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes
- (2016) Kristine R. Broglio et al. JAMA Oncology
- Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy
- (2016) Sarah S. Mougalian et al. JAMA Oncology
- ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
- (2015) Sasagu Kurozumi et al. BMC CANCER
- Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico
- (2015) Cynthia Villarreal-Garza et al. BREAST
- Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab
- (2015) Arvind M. Shinde et al. BREAST
- Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy
- (2015) Shiwei Liu et al. BREAST CANCER RESEARCH AND TREATMENT
- Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy
- (2015) A M Gonzalez-Angulo et al. BRITISH JOURNAL OF CANCER
- Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
- (2015) Anne-Sophie Hamy-Petit et al. BRITISH JOURNAL OF CANCER
- Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer
- (2015) Erica L. Mayer et al. Clinical Breast Cancer
- High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer to a Novel Nonanthracycline Neoadjuvant Chemotherapy
- (2015) Amelia B. Zelnak et al. Clinical Breast Cancer
- Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype
- (2015) Eun Sook Ko et al. KOREAN JOURNAL OF RADIOLOGY
- High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer
- (2015) T. Kogawa et al. ONCOLOGIST
- Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy
- (2015) Shiwei Liu et al. TUMOR BIOLOGY
- Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study
- (2015) Yi-Zi Zheng et al. Oncotarget
- Neoadjuvant Therapy
- (2015) Howard (Jack) West et al. JAMA Oncology
- Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status
- (2014) Maki Tanioka et al. BREAST
- Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)
- (2014) M. Takada et al. BREAST CANCER RESEARCH AND TREATMENT
- Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data
- (2014) J.-Y. Pierga et al. CLINICAL CANCER RESEARCH
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
- (2014) Evandro de Azambuja et al. LANCET ONCOLOGY
- Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2014) Luca Gianni et al. LANCET ONCOLOGY
- Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer
- (2014) HIDEMI KAWAJIRI et al. Oncology Letters
- Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
- (2013) V. Guarneri et al. ANNALS OF ONCOLOGY
- Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer
- (2013) M. M. Kim et al. ANNALS OF ONCOLOGY
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification
- (2013) S. Saracchini et al. BREAST
- Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients
- (2013) A. Sánchez-Muñoz et al. Clinical & Translational Oncology
- Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer
- (2013) G.C. Zhang et al. Current Oncology
- Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
- (2013) Clara Natoli et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer
- (2013) Jung Hoon Cho et al. JOURNAL OF SURGICAL ONCOLOGY
- Survival Outcomes of Breast Cancer Patients Who Receive Neoadjuvant Chemotherapy: Association with Dynamic Contrast-enhanced MR Imaging with Computer-aided Evaluation
- (2013) Ann Yi et al. RADIOLOGY
- Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice
- (2012) Sonia Pernas et al. BREAST CANCER RESEARCH AND TREATMENT
- Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy
- (2012) Na Rae Ju et al. BREAST CANCER RESEARCH AND TREATMENT
- Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
- (2012) Laura J. Esserman et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis
- (2012) Bohuslav Melichar et al. MEDICAL ONCOLOGY
- Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab
- (2012) Hideyuki Ohzawa et al. Breast Cancer
- Pathologic Response to Short Intensified Taxane-free Neoadjuvant Chemotherapy in Patients with Highly Proliferative Operable Breast Cancer
- (2011) Christophe Le Tourneau et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
- (2011) L. Yao et al. ANNALS OF ONCOLOGY
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
- (2011) Peter A Fasching et al. BMC CANCER
- Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01
- (2011) Seock-Ah Im et al. BREAST CANCER RESEARCH AND TREATMENT
- Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
- (2011) Soley Bayraktar et al. CANCER
- Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
- (2011) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
- (2011) Sylvain Ladoire et al. JOURNAL OF PATHOLOGY
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Long-term Outcome and Pattern of Relapse after Neoadjuvant Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-positive Primary Breast Cancer
- (2009) C. Shimizu et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started